BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ViaDor-GLP1 agonist: Phase Ib data

Data from a 4-way crossover Phase Ib trial in 14 Type II diabetics showed that single doses of 3 patch formulations of once-daily ViaDor-GLP1 agonist were well tolerated, with an...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >